vTv Therapeutics Inc. (NASDAQ:VTVT) Receives Average Rating of "Moderate Buy" from Analysts

Key Points

• "Moderate Buy" consensus from six analysts (five buy ratings, one sell) with an average 1‑year target price of $53.00.
• vTv reported Q results of a ($0.58) EPS, beating the consensus estimate of ($1.09) by $0.51, with revenue roughly flat at about ($0.02) million for the quarter.
• vTv is a clinical‑stage biopharma whose lead candidate, azeliragon for early‑stage Alzheimer’s, completed Phase II/III, and institutional investors (including Goldman Sachs and Baker Bros.) have recently increased positions, with institutions owning 17.51%.

vTv Therapeutics Inc. (NASDAQ:VTVT - Get Free Report) has been given an average recommendation of "Moderate Buy" by the six brokerages that are currently covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation and five have issued a buy recommendation on the company. The average 1 year target price among brokers that have covered the stock in the last year is $53.00.

A number of analysts have recently issued reports on VTVT shares. Wall Street Zen upgraded vTv Therapeutics from a "sell" rating to a "hold" rating in a report on Saturday, March 14th. HC Wainwright reiterated a "buy" rating and set a $47.00 price target (up from $36.00) on shares of vTv Therapeutics in a report on Friday, December 19th. Weiss Ratings reissued a "sell (d-)" rating on shares of vTv Therapeutics in a research note on Monday, December 29th. Evercore began coverage on vTv Therapeutics in a research note on Thursday, March 12th. They issued an "outperform" rating and a $44.00 price objective for the company. Finally, TD Cowen started coverage on vTv Therapeutics in a research report on Monday, January 5th. They set a "buy" rating for the company.

vTv Therapeutics Price Performance

Shares of VTVT opened at $36.00 on Friday. The company has a 50-day moving average of $35.52 and a two-hundred day moving average of $30.14. The stock has a market cap of $141.77 million, a price-to-earnings ratio of -10.75 and a beta of 0.44. vTv Therapeutics has a one year low of $14.00 and a one year high of $44.00.

vTv Therapeutics (NASDAQ:VTVT - Get Free Report) last released its quarterly earnings results on Tuesday, March 10th. The biotechnology company reported ($0.58) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.09) by $0.51. The firm had revenue of ($0.02) million for the quarter.

Institutional Trading of vTv Therapeutics

Several institutional investors have recently made changes to their positions in VTVT. Goldman Sachs Group Inc. purchased a new position in vTv Therapeutics during the fourth quarter valued at approximately $221,000. 683 Capital Management LLC acquired a new stake in vTv Therapeutics during the fourth quarter valued at $731,000. Geode Capital Management LLC raised its stake in shares of vTv Therapeutics by 84.3% during the 4th quarter. Geode Capital Management LLC now owns 28,194 shares of the biotechnology company's stock worth $1,128,000 after purchasing an additional 12,896 shares in the last quarter. Finally, Baker BROS. Advisors LP raised its stake in shares of vTv Therapeutics by 52.4% during the 3rd quarter. Baker BROS. Advisors LP now owns 148,314 shares of the biotechnology company's stock worth $3,463,000 after purchasing an additional 51,000 shares in the last quarter. 17.51% of the stock is currently owned by institutional investors and hedge funds.

vTv Therapeutics Company Profile

vTv Therapeutics, Inc is a clinical-stage biopharmaceutical company headquartered in Westport, Connecticut, focused on discovering and developing orally administered small-molecule therapies for chronic diseases. Employing its proprietary medicinal chemistry platform, the company seeks to generate novel compounds that modulate key disease pathways while optimizing safety and pharmacokinetic properties.

The company's lead candidate, azeliragon (TTP488), is an oral inhibitor of the receptor for advanced glycation end products (RAGE) and has completed Phase II/III clinical evaluation in early-stage Alzheimer's disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.